BSX is one of the largest medical-device companies in the world, focused mainly on cardiovascular, endoscopy, urology and neuromodulation. Think catheters, ablation systems, stents, implantable devices and other products used during minimally invasive procedures
The stock is around $45 as of September 24, 2026, with a market capitalization of roughly $65B. Trailing P/E around 18x and a forward P/E around 13x. The margins are good, the growth is decent.
It's a healthy business (pun intended..)
From 2022 to 2025, revenue increased from roughly $12.7B to $20.1B. Organic growth reached 12.3% in 2023, 16.4% in 2024 and 15.8% in 2025. In 2025, Cardiovascular- about two-thirds of total revenue - grew 20.8% organically. In 2026 there was some slowdown, which is why share price was in decline this year...
On August 3, Boston scientific CEO Michael Mahoney bought shares at a weighted average price of $48.33 for approximately $9 million. Rep. Gilbert Ray Cisneros Jr. disclosed a purchase of Boston Scientific shares on August 18. The disclosure was filed on September 10.
What do you think, any doctors here?